A5049406196- Health, Medicine and Society
- Cancer Treatment and Pharmacology
- Pain Management and Opioid Use
- Healthcare Systems and Practices
- Prostate Cancer Treatment and Research
- Palliative Care and End-of-Life Issues
- Cancer survivorship and care
- Pharmacological Effects and Toxicity Studies
- Pediatric Pain Management Techniques
- Prostate Cancer Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Management of metastatic bone disease
- Childhood Cancer Survivors' Quality of Life
- Clinical practice guidelines implementation
- Colorectal Cancer Treatments and Studies
- Pain Management and Placebo Effect
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Nutrition and Health in Aging
- Chemotherapy-related skin toxicity
- Anesthesia and Pain Management
- Pain Mechanisms and Treatments
- Cancer Diagnosis and Treatment
- Bone health and treatments
- Multiple and Secondary Primary Cancers
Délégation Centre-Est
2010-2024
Association Francophone pour les Soins Oncologiques de Support
2013-2023
Institut Bergonié
1999-2020
Institut de Cancérologie de Lorraine
1999-2016
Université de Lorraine
2016
Centre d'expertise et de recherche en infrastructures urbaines
1996-2013
Fédération Francophone de Cancérologie Digestive
1996-2013
Institut Curie
1996-2009
Université Jean Monnet
2003
Centre d'Investigation Clinique de Nantes
1999
PURPOSE This trial investigated the toxicity and efficacy of docetaxel as first-line chemotherapy in women with heavily pretreated advanced breast cancer. PATIENTS AND METHODS From April 1992 to August 1992, 35 patients cancer from 29 65 years age a performance status 0 2 were entered onto study. Docetaxel 100 mg/m2 was administered every 3 weeks 1-hour infusion on day 1 without routine premedication for hypersensitivity reactions. Thirty-one assessable response. Previous adjuvant had been...
To investigate the potential benefit of reintroducing docetaxel chemotherapy in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) who had initially responded to first-line docetaxel-based regimen.Records were evaluated retrospectively from French mCRPC been included seven controlled clinical studies as treatment. We identified confirmed responders treatment, discontinued for reasons other than disease progression or unacceptable toxicity, and received further...
Abstract This prospective national multicenter study was carried out to estimate the prevalence and incidence of chronic pain with or without neuropathic characteristics in patients cancer France. All consecutive outpatients (n = 1885) seen over 2 weeks for treatment 12 oncology units were invited participate study, 1805 included. Patients underwent a clinical examination during visit 1, questionnaire completed detect (defined as daily at least 3 months), characterize its intensity,...
We report the results of Subcutaneous Administration Propeukin Program (SCAPP) II trial an outpatient treatment in renal cell carcinoma using interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) administered subcutaneously combination with fluorouracil (5-FU). The objective this multicenter was to confirm that IL-2, IFN-alpha, 5-FU leads a response rate greater than 20%.Patients metastatic were included study. During induction phase treatment, which lasted 10 weeks, IL-2 IFN-alpha three...
This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on hematologic tolerance patients with sarcoma treated mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy.Forty-eight metastatic or locally advanced soft tissue were, following first cycle combination 60 mg/m2, ifosfamide 7.5 g/m2, dacarbazine 900 mg/m2 given days 1 3, receive either...
140 Background: ADT is standard treatment for metastatic PCa. Recently, the E3805 trial reported a survival benefit (ADT+D) in high volume disease (HVD) patients, whereas GETUG-15 did not demonstrate improvement among less selected group of patients (pts) with hormone-naïve We report an updated analysis overall (OS) GETUG 15 and aligned definition HVD low (LVD) subgroups. Methods: Long-termOS was analyzed intention-to-treat population (n=385 pts). Additionally, we retrospectively assessed...
Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but uncertain benefit a nonmetastatic, high-risk setting.To assess ADT patients presenting with rising prostate-specific antigen (PSA) levels after primary local and factors no evidence disease.This open-label, phase 3, randomized superiority trial comparing vs alone enrolled from 28 centers France between June 4, 2003, September 25, 2007; final follow-up was conducted April...
Abstract Background An international consensus proposed in 2011 a definition and classification system for cachexia (CAX), mainly based on weight loss, sarcopenia [skeletal muscle mass (SMM) loss], inflammation, anorexia. The aim of this study was to stage CAX non‐small‐cell lung cancer (NSCLC) patients by using the Fearon criteria supported quantifiable parameters. Methods This cross‐sectional non‐interventional multicentre study. SMM assessed analysing L3 computed tomography‐scan images....
Electronic patient-reported outcome (ePRO) systems for symptom monitoring in patients with cancer have shown quality of life and survival benefits controlled trials. They are beginning to be used routine oncology practice. Many software developers provide solutions clinicians, but how should clinicians decide which system use? We propose a synthesis the main questions regarding effectiveness, safety, functionality an ePRO that clinician ask providers assist selection product order obtain...